LOWER URINARY TRACT SYMPTOMS, BENIGN PROSTATIC HYPERPLASIA, AND METABOLIC SYNDROME
Introduction and Objective: The aim of this study was to evaluate the relationship between lower urinary tract symptoms (LUTS), benign prostatic hyperplasia, and metabolic syndrome. Methods: 381 patients, over 45 years, with metabolic syndrome were divided in 2 groups: group A – 310 patients with BHP (MetS+BPH) and, group B – 71 patients without BPH (MetS-BPH). Fasting concentrations of plasma glucose, HbA1c, serum lipides (total cholesterol, triglycerides, high-density lipoprotein HDL- C), insulin, and prostate-specific antigen (PSA) were measured under standardised conditions at baseline, 6 months and one year. IR (insulin resistance) was determinated using homeostasis model assessment (HOMA-IR). The presence of LUTS was assessed using the International Prostate Symptoms Score. The prostate gland volume was measured using transrectal ultrasound (prostate volume over 30 cm3 was considered prostatic hyperplasia). Results: Prevalence of severe LUTS was 14.8% (n=46) in BPH patients and 4.2% (n=3) patients without prostatic diseases (0.032). Prevalence of moderate LUTS was 74.2% (n=230) in BPH patients and 78.9% (n=56) patients without prostatic diseases (0.032). IPSS score correlated positively with age, BMI, triglycerides, HDL-cholestrol, and HbA1c. Conclusion: LUTS are frequent in metabolic syndrome patients with or without benign prostatic hyperplasia. In patients with all five components of MetS there was an increased prevalence of LUTS. Resulting from this study it is our reccomendation that patients with MetS need follow up/seek advice from an urological specialist as well.